2O9 Stock Overview
Develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management kidney diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Renalytix Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.082 |
| 52 Week High | UK£0.62 |
| 52 Week Low | UK£0.081 |
| Beta | 2.07 |
| 11 Month Change | -12.37% |
| 3 Month Change | -32.64% |
| 1 Year Change | -62.95% |
| 33 Year Change | -98.96% |
| 5 Year Change | n/a |
| Change since IPO | -99.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2O9 | DE Healthcare Services | DE Market | |
|---|---|---|---|
| 7D | -6.3% | 0.05% | 0.2% |
| 1Y | -63.0% | -32.1% | 8.5% |
Return vs Industry: 2O9 underperformed the German Healthcare Services industry which returned -32.1% over the past year.
Return vs Market: 2O9 underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| 2O9 volatility | |
|---|---|
| 2O9 Average Weekly Movement | 9.6% |
| Healthcare Services Industry Average Movement | 5.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 2O9's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2O9's weekly volatility has decreased from 34% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | James McCullough | renalytix.com |
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management kidney diseases in the United States. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Renalytix Plc Fundamentals Summary
| 2O9 fundamental statistics | |
|---|---|
| Market cap | €30.89m |
| Earnings (TTM) | -€26.92m |
| Revenue (TTM) | €2.26m |
13.7x
P/S Ratio-1.1x
P/E RatioIs 2O9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2O9 income statement (TTM) | |
|---|---|
| Revenue | US$2.35m |
| Cost of Revenue | US$2.05m |
| Gross Profit | US$299.00k |
| Other Expenses | US$28.33m |
| Earnings | -US$28.03m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.085 |
| Gross Margin | 12.71% |
| Net Profit Margin | -1,191.75% |
| Debt/Equity Ratio | -72.8% |
How did 2O9 perform over the long term?
See historical performance and comparison